Validation of ICD ‐10 Diagnosis Codes for Identification of Acute Myocardial Infarction From a US Integrated Healthcare System
Pharmacoepidemiology and Drug Safety · 2025
DOI: 10.1002/pds.70179 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von Jeff Slezak und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA. Hauptthemen laut MEDLINE: International Classification of Diseases, Myocardial Infarction, Electronic Health Records, Delivery of Health Care, Integrated. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Purpose
Contemporary epidemiologic research on acute myocardial infarction (AMI) using electronic health records (EHR) relies on International Classification of Diseases, 10th Revision, Clinical Modification (ICD‐10‐CM) codes, but limited studies have been conducted to validate these codes in the United States. Therefore, this study aimed to validate AMI events identified by ICD‐10‐CM diagnosis codes.
Methods
The study was conducted as part of a hepatitis B vaccine safety study. Suspected cases of AMI were identified using ICD‐10‐CM codes (I21.* or I22.*) in any diagnosis position from August 7, 2018 to November 30, 2020. Cases were adjudicated independently by two cardiologists, with a third resolving disagreements. Positive predictive value (PPV) was calculated as the percentage of suspected cases that were confirmed as definite or probable AMI on review, and exact binomial 95% confidence intervals (CI) were estimated.
Results
Of 202 potential AMI events identified among 69 625 individuals, 162 (80.2% [95% CI: 74.0%–85.5%]) were confirmed. Encounters with AMI coded as the principal discharge diagnosis code were more likely to be confirmed (86.8% [80.5%–91.6%]) than those with AMI in another diagnosis position (55.8% [39.9%–70.9%]), while patients with a history of congestive heart failure and peripheral vascular disease had lower PPV compared to those without (83.2% [76.7%–88.6%] and 82.9% [76.4%–88.3%], respectively).
Conclusion
We found that over 80% of AMI cases identified with ICD‐10‐CM codes were confirmed upon cardiologist adjudication. Cases not coded in the principal diagnosis position were much less likely to be confirmed, and care should be taken when using them in EHR‐based research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
- Department of Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- Department of Cardiology, Kaiser Permanente Southern California, Los Angeles, California, USA.
- Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California, USA.
ORCID-Profile: Jeff Slezak
Zitieren
APA
Slezak, J., Bruxvoort, K. J., Sy, L. S., Ackerson, B. K., Shen, A. Y., Lee, M. S., Gupta, N., Qian, L., Qiu, S., Solano, Z., & Reynolds, K. (2025). Validation of ICD ‐10 Diagnosis Codes for Identification of Acute Myocardial Infarction From a US Integrated Healthcare System. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70179
Vancouver
Slezak J, Bruxvoort KJ, Sy LS, Ackerson BK, Shen AY, Lee MS, et al. Validation of ICD ‐10 Diagnosis Codes for Identification of Acute Myocardial Infarction From a US Integrated Healthcare System. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70179
BibTeX
@article{Slezak2025,
author = {Slezak, Jeff and Bruxvoort, Katia J and Sy, Lina S and Ackerson, Bradley K and Shen, Albert Y-J and Lee, Ming-Sum and Gupta, Nigel and Qian, Lei and Qiu, Sijia and Solano, Zendi and Reynolds, Kristi},
title = {Validation of ICD ‐10 Diagnosis Codes for Identification of Acute Myocardial Infarction From a US Integrated Healthcare System},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2025},
doi = {10.1002/pds.70179}
}
EUVIMED